Immune checkpoint inhibitors (ICIs) are a newly developed component of cancer care that expands the treatment possibilities for patients. Their use has been associated with several immune-related adverse events, including ICIinduced sarcoidosis-like reactions. This article reviews the data concerning ICI-induced sarcoidosis-like reactions currently available in the medical literature. These reactions have been reported in three classes of ICIs: anti-cytotoxic Tlymphocyte associated protein 4 antibodies, programmed death 1 inhibitors and programmed death ligand 1 inhibitors. These reactions are indistinguishable from sarcoidosis with a similar histology, pattern of organ involvement, and pattern of clinical manifestations. The most common locations to observe granulomatous inflammation from these reactions is in intrathoracic locations (the lung and/or mediastinal lymph nodes) and the skin. The median time between initiation of an ICI and the development of a sarcoidosis-like reaction averaged 14 weeks. Clinicians have opted to use corticosteroids and/or discontinue the ICI, or take no action when these reactions have developed. Regardless of whether the clinician performed an intervention or not, these reactions have uniformly improved or resolved after ICI-treatment, which provides additional temporal evidence supporting the presence of a sarcoidosis-like reaction as opposed to sarcoidosis. There is even evidence that the development of an ICI-induced sarcoidosis-like reaction suggests that the ICI is effective as an anti-tumor agent and should be continued. As is the case for sarcoidosis, sarcoidosis-like reactions do not mandate antisarcoidosis therapy, especially if the condition is asymptomatic. When treatment of sarcoidosis-like reaction is required, it may be prudent to continue ICI therapy and add antisarcoidosis therapy because standard antisarcoidosis regimens seem to be effective. Further research into the mechanisms involved in the development of ICIinduced sarcoidosis-like reactions may give insights into the immunopathogenesis of sarcoidosis.
Introduction
Several drugs have been associated with the development of syndromes indistinguishable from sarcoidosis that are described as "sarcoidosis-like reactions." Because the exact immunopathogenesis of sarcoidosis is unknown, it is not clear if these drugs are truly causing sarcoidosis, rendering the immune system more susceptible to the development of sarcoidosis, or are distinct entities from sarcoidosis. Drugs associated with sarcoidosis-like reactions include interferon-a, highly active antiretroviral therapy, and tumor necrosis factor alpha antagonists. [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] Immunotherapy is a newly developed component of cancer care that expands the treatment possibilities for *Corresponding author.
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patients. Unfortunately, immunotherapy may also generate toxicities related immune system dysregulation and/or stimulation called immune-related adverse events (irAEs). IrAEs may potentially affect any tissue, and may manifest as a sarcoidosis-like reaction, reactive lymphadenopathy, dermatological manifestations such as plaques and nodules, gastrointestinal manifestations such as colitis, and endocrine deregulation including hypophysitis and hypothyroidism. 11, 12 Without performing a tissue biopsy, it may be problematic to differentiate a sarcoidosis-like reaction from an alternative cause of an irAE. For example, although a sarcoidosis-like reaction may cause mediastinal lymphadenopathy on chest imaging, an identical radiographic appearance may occur from an irAE causing reactive lymphadenopathy in mediastinal lymph nodes. 13 Although biopsies are not always performed to establish if an irAE represents a sarcoidosis-like reaction as opposed to other forms of irAEs, they are often indicated to exclude infectious or malignant processes that may have similar clinical presentations to irAEs.
Recently, several reports have described an association between the use of immune checkpoint inhibitors (ICIs) and the development of sarcoidosis-like reactions. ICIs inactivate proteins that have been synthesized by immune cells such as T lymphocytes as well as tumor cells that inhibit antitumor T cell activity.
14 Inactivation of these proteins by ICIs has led to durable clinical responses in several malignancies. 15 However, ICI-induced activation of the immune system may have additional consequences, including the development irAEs and, specifically, sarcoidosis-like reactions. In this article, we review the evidence for the association of ICI therapy and the development of sarcoidosis-like reactions, discuss the potential mechanisms for this association, and explore how this association may provide insights into the pathogenesis of sarcoidosis.
Proposed Mechanisms of Checkpoint Inhibitors Causing Sarcoidosis-Like Reactions
Ipilimumab is a humanized monoclonal antibody directed against cytotoxic T-lymphocyte associated protein 4 (CTLA-4) that is approved for the treatment of metastatic melanoma and has been shown to increase survival in these patients. 16 Blockade of CTLA-4 is thought to elicit an antitumor immune response by overcoming CTLA-4-mediated T lymphocyte suppression. Consequently, it prolongs T cell activation and restores T cell proliferation, thus amplifying T cellmediated immunity and the capacity of the patient to mount an effective antitumor immune response. 17 Recent data suggest that in patients with melanoma, ipilimumab can enhance both immune responses and humoral immunity mediated by different T cell populations. 18 The clinical response to ipilimumab has been shown to correlate with a subsequent treatment-induced increase in lymphocyte counts and an increased expression of T helper cell 1 (Th1)-associated markers. 19, 20 The emergence of lymphocytes with an increased expression of Th1-associated markers could potentially induce a sarcoidosis-like reaction as these cells are abundant in active sarcoidosis and thought to be integral to the development of the sarcoid granuloma. 21 Another proposed mechanism for ICI-induced sarcoidosis-like reactions involves an increase in the number and function of Th17 cells that has been shown in melanoma patients who received anti-CTLA-4 treatment. 22, 23 Th17 cells are thought to have an integral role in the development of sarcoid granulomas and may also promote the development of sarcoidosis induced fibrosis. 24 In addition, there is evidence of a Th17 cell-T regulatory cell imbalance in sarcoidosis, with an increased Th17/T regulatory cell ratio both in the peripheral blood and bronchoalveolar lavage fluid of sarcoidosis patients. 25 Additionally, a recent large casecontrol study confirmed an association between genetic variants near the interleukin 23 receptor (which promotes Th17 responses) in different cohorts of subjects with sarcoidosis. 26 Immune checkpoint antibodies that inhibit the programmed cell death protein 1 (PD-1)/PD-ligand 1 pathway have shown antitumor activity against numerous malignancies and recently gained regulatory approval as single-agent therapy for the treatment of metastatic malignant melanoma and NSCLC. 27 Inhibitory receptor PD-1 and its ligand PD-L1 also appear to play a role in the immunopathogenesis of sarcoidosis. Braun et al. showed that increased numbers of PD-1þCD4þ T cells are present in the blood compartment and bronchoalveolar lavage (BAL) of pulmonary sarcoidosis patients. 28 Additionally, PD-L1 has been shown to be upregulated in sarcoid lung granulomas but not in healthy lung tissue. Furthermore, in vitro blockade of the PD-1 pathway restored the proliferative capacity of sarcoidosis CD4þ T cells to levels consistent with healthy control subjects. Because of this established association of PD-1 and PD-L1 and the granulomatous inflammation of sarcoidosis, it seems paradoxical that checkpoint inhibitors that block PD-1 and PD-L1 have been shown to potentiate the Th1 T cell-mediated response and cause sarcoidosis. It has been postulated that this paradoxical response may involve interleukin 17-producing cells, including CD4þ Th17 cells, that are known to be expanded in sarcoidosis. 29 Researchers have shown an association between the presence of abnormally high numbers of circulating Th17.1 cells in melanoma patients before receiving anti-PD-1 antibody therapy and the onset of sarcoidosis. 30 This suggests that anti-PD-1 antibody therapy may amplify the effects of Th17.1 cells to cause sarcoidosis.
Clinical Presentation of Sarcoidosis-Like Reactions: Time Course for Drug Initiation, Phenotypic Expression, Clinical Course Table 1 shows the currently reported cases of sarcoidosis-like reactions associated with the use of ICIs. The most common ICI associated with sarcoidosis-like reactions is ipilimumab, although cases have been reported with nivolumab, pembrolizumab, and anti-PD-L1 antibody therapy. Most of the underlying malignancies have been melanoma, which probably relates to the clinical indication for ICI use. ICI-related sarcoidosis-like reactions have also been reported in patients with prostate carcinoma, Hodgkin's lymphoma, and uterine leiomyosarcoma. The time to onset of sarcoidosis-like reactions after initiating ICIs has ranged from 3 weeks to almost 2 years, although all cases except one occurred within 36 weeks. There is not an obvious ICI dose threshold for the development of ICI-related sarcoidosislike reactions. Corticosteroid treatment or other antisarcoidosis treatment has not been required for all cases of ICI-related sarcoidosis-like reactions. The most common factor that led to the initiation of corticosteroid treatment was persistent patients' symptoms, including fatigue, fever, and dyspnea. The lung and skin were common organs involved with ICI-related sarcoidosislike reactions.
Sarcoidosis-like reactions during anti-CTLA-4 treatment most commonly occur in the lung, and typically present with pulmonary nodules and mediastinal lymphadenopathy (Fig. 1) . 31, 32 Rarely, coexistent intraabdominal lymphadenopathy is observed. 33 Groundglass pulmonary infiltrates are uncommon. 34 Similar to non-drug-induced sarcoidosis, sarcoidosis-like reactions show fluorodeoxyglucose uptake in involved tissues on positron-emission tomography scans. 31 Two retrospective radiographic studies have examined the incidence of thoracic sarcoid-like reactions in patients undergoing anti-CTLA-4 treatment. Bronstein et al. 35 reported that 8 of 119 patients (6.7%) who received anti-CTLA-4 treatment (tremelimumab or ipilimumab) for advanced metastatic melanoma presented clinically silent radiologically benign thoracic lymphadenopathy. These radiologic manifestations were noticed after a median interval time of 6.3 months after treatment was initiated. In a more recent study, 8 of 147 patients (5%) undergoing ipilimumab treatment for melanoma developed radiologically sarcoid-like lymphadenopathy after a median interval time of 3.2 months from the initiation of therapy. 33 Although, as previously mentioned, the presence of mediastinal adenopathy does not secure the diagnosis of a sarcoidosis-like reaction and could represent reactive lymphadenopathy associated with an irAE, three of eight patients also had concomitant pulmonary parenchymal findings consistent with sarcoidosis.
The skin is the second most commonly involved organ with anti CTLA-4-induced sarcoidosis-like reactions. Dermatological symptoms often precede the detection of pulmonary infiltrates and lead patients to seek medical care. These skin lesions can range from localized plaques and nodules to generalized cutaneous eruptions. 32, [36] [37] [38] Lofgren syndrome as well as cutaneous granulomatous infiltration of a tattoo has been reported in a patient with metastatic urothelial cancer on combination therapy with a CTLA-4 and a PD-1 inhibitor. 39 Similar to sarcoidosis, the phenotypic expression of sarcoidosis-like reactions can involve organs other than Mediastinal lymph node (15, 65), skin (11, 48) , lung (10, 43) , extrathoracic lymph node (7, 30) , spleen (4, 17), neural tissue (2, 9), eye (1, 4), bone (1, 4) Organ biopsy showing granulomas (n, %) c Skin (11, 48) , mediastinal lymph node (8, 35) , lung (6, 26) , extrathoracic lymph node (2, 9), spleen (1, 4) Course of action (n, %) Discontinuation of ICI plus corticosteroid therapy (7, 30) , discontinuation of ICI (6, 26) , corticosteroid therapy (5, 22) , no action taken (3, 13), not specified (2, 9) Outcome (n, %) Improvement (11, 48) , resolution (10, 43), not specified (2, 9)
a Based reports found in the reference list. the lung or skin. Such organ involvement is often identified via the restaging of the underlying malignancy with 18F-fluorodeoxyglucose/positron-emission tomography (FDG/PET). Granulomatous infiltration of the spleen from an ICI-induced sarcoidosis-like reaction can present as splenomegaly with a homogenous uptake of 18FDG or small intrasplenic lesions without splenomegaly. 31, 40 Ipilimumab-related interstitial nephritis may exhibit pathologic appearances consistent with granulomatous nephritis. 41, 42 Pituitary granulomas and polyneuropathy have also been reported as complications of ipilimumab treatment. 43, 44 Elevations of the serum angiotensinconverting enzyme level have also been reported with ICI-induced sarcoidosis-like reactions. 39, 45 There are significantly less data regarding the development of sarcoidosis-like reactions with PD-1 and PDL-1 checkpoint inhibitors. Monotherapy with nivolumab, an anti-PD-1 drug, for metastatic melanoma has been associated with bilateral hilar and mediastinal lymphadenopathy and skin involvement in one case and pulmonary infiltrates with facial edema in another. 46, 47 Pulmonary and cutaneous sarcoidosis-like reactions have developed in a patient treated with pembrolizumab, another anti-PD-1 drug, for Hodgkin lymphoma and uterine leiomyosarcoma. 48, 49 In a multicenter phase 1 trial of the PD-L1 inhibitor atezolizumab, a sarcoidosis-like reaction developed in 1 patient of 207. 27 In another phase 2 trial of atezolizumab as second-line therapy in advanced urothelial carcinoma, 1 patient of 315 developed non-necrotizing granulomatous hepatitis. 50 There are also reported cases of sarcoid-like reactions in patients receiving multiple checkpoint inhibitors simultaneously or successively as part of their antitumor treatment. Cutaneous sarcoidosis has been reported in a female patient with metastatic lung adenocarcinoma receiving ipilimumab and nivolumab. 51 Another patient treated with pembrolizumab for metastatic melanoma because of disease progression on ipilimumab presented with thoracic and skin sarcoidosis. 52 The reported incidence of sarcoidosis-like reactions appears to be different between the two main classes of ICIs. As mentioned previously, the reported incidence of radiological diagnoses of sarcoidosis-like reactions during anti-CTLA-4 treatment is between 5% and 6.7%. 33, 35 This particular irAE is less common with the use of anti-PD-1/PD-L1 blockades, having been reported in 1 of 207 patients (<0.5%) who received anti-PD-L1 regimen BMS-39886 and in 2 of 908 patents (0.2%) in a French registry of patients treated with anti-PD1 and anti-PD-L1 regimens. 27, 53 This difference in irAE incidence could be possibly be attributed the fact that, although anti-PD-1 immune checkpoint inhibitors may cause sarcoidosislike reactions, downregulation of PD-1 expression on CD4þT cells has been associated with spontaneous resolution of sarcoidosis. 28 The histopathology from reported cases of ICIinduced sarcoidosis-like reactions is identical to that of sarcoidosis. The biopsy specimens reveal focal infiltration by noncaseating epithelioid and giant cell granulomas. These lesions can coalesce into micronodules. 43 No malignant cells or eosinophils have been described, whereas Grocott's methenamine silver and acid-fast bacilli stains are negative.
Management of Checkpoint InhibitorInduced Sarcoidosis-Like Reactions
To date, no case of a sarcoidosis-like reaction has been reported that was refractory to corticosteroid treatment or discontinuation of checkpoint inhibitors. In a case series of six patients who developed checkpoint inhibitor-induced sarcoidosis-like reactions, all of them showed resolution of lymphadenopathy on lung imaging after checkpoint inhibitor discontinuation in a median interval to resolution of 3.1 months, and only one of them received concomitant corticosteroids. 33 We believe that if checkpoint inhibitor therapy shows a significant beneficial effect against a cancer but induces a sarcoidosis-like reaction, it may be prudent to continue checkpoint inhibitor therapy and add antisarcoidosis therapy. As is the case for sarcoidosis, sarcoidosis-like reactions do not mandate antisarcoidosis therapy, especially if the condition is asymptomatic. Danlos et al. 46 reviewed nine case reports of sarcoid-like reactions induced by ipilimumab used to treat melanoma and found that 56% (five of nine) were symptomatic and did not require antisarcoidosis therapy.
In cases of a sarcoidosis-like reaction where the checkpoint inhibitor therapy has been equivocal or ineffective, discontinuation of chemotherapy could be considered, which should resolve the sarcoidosis-like reaction.
Another reason not to discontinue an checkpoint inhibitor when an irAE, or specifically, a sarcoidosis-like reaction occurs is that it has been postulated that an irAE actually depicts an effective granulomatous antimelanoma response due to inflammation and crossreaction with melanoma antigens as a result of anti-CTLA-4 treatment. 43 There is significant clinical evidence supporting an association between anti-CTLA-4-induced irAEs and a beneficial antitumor response. O'Regan et al. 54 reviewed a large number of clinical ipilimumab studies and found that the development of an irAEs was predictive of a better clinical response. Additionally, cohorts of melanoma patients in ipilimumab trials with high irAE rates were those with the longest overall survivals. 55 In a recent retrospective analysis, cutaneous irAEs were associated with improved survival in melanoma patients treated with nivolumab. 56 In another retrospective study of 119 patients who received anti-CTLA-4 treatment, the 20 patients with radiologic manifestations of irAEs, including sarcoidosis-like reactions, had a better response compared to the 99 patients without any radiologic manifestations of an irAE: there was a disease control rate of 55% and a 25% complete response rate in the irAE group versus 10% and 3%, respectively, among the patients who did not develop irAEs. 35 
Conclusion
With the increasing use of checkpoint inhibitors for the treatment of cancers, clinicians should become familiar with associated sarcoidosis-like reactions. A sarcoidosis-like reaction may be misinterpreted on imaging studies as treatment failure and tumor progression, similar to the other immune-mediated adverse events. A biopsy of tissue suspected to be involved should be strongly considered to differentiate immunemediated adverse events from tumor progression if the latter is a reasonable possibility. At present, it is unknown whether a sarcoid-like reaction of malignancy and sarcoidosis can be differentiated by clinical tests or biomarkers, including biomarkers associated with sarcoidosis activity. Although sarcoidosis biomarkers have been examined in some of these cases and have been elevated at times, these biomarkers have not been evaluated consistently or rigorously so that definite conclusions can be made about their role in distinguishing sarcoidosis from sarcoidosis-like reactions.
The presence of an ICI-induced sarcoidosis-like reaction does not mandate therapy. Therapy of these reactions is only indicated if they result in significant symptoms or organ dysfunction. These reactions typically respond to corticosteroid therapy. Although ICI may be continued when a sarcoidosis-like reaction develops, these reactions usually resolve if the ICI is discontinued. Further research into the immunologic mechanisms involved in the development of ICI-induced
